The Obesity Drug Impact
September 19, 2024
No Comments
Sales of GLP-1 agonists obesity drugs Ozempic and Wegovy, which are semaglutides, and Mounjaro and Zepbound, which are tirzepatides, were $6 billion in 2023. Morgan Stanley Research predicts the global market for obesity drugs to